Cellectis Adr (CLLS)

Jul 02, 2026

European ADRs Jumped As Biotech Led The Pack - Finimize

Jul 02, 2026

Jul 01, 2026

Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings - TradingView

Jul 01, 2026

Jun 29, 2026

European ADRs Rose As Biopharma Names Led The Pack - Finimize

Jun 29, 2026

Jun 27, 2026

A14QZE Forecast — Price Target — Prediction for 2027 - TradingView

Jun 27, 2026

Jun 26, 2026

Cellectis S.A. Sponsored ADR Actuals & Estimates (NASDAQ:CLLS) - TradingView

Jun 26, 2026

Jun 26, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 26, 2026

Jun 18, 2026

European ADRs Slip, Even As Biotech Names Edge Higher - Finimize

Jun 18, 2026

Jun 11, 2026

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - GlobeNewswire Inc.

Jun 11, 2026

Jun 10, 2026

Cellectis stock rises on FDA therapy designation - Investing.com

Jun 10, 2026

Jun 10, 2026

Cellectis stock rises on FDA therapy designation By Investing.com - Investing.com India

Jun 10, 2026

Jun 02, 2026

CLLS Stock Chart | CELLECTISADR (NASDAQ:CLLS) - ChartMill

Jun 02, 2026

May 28, 2026

Barclays initiates Cellectis stock with overweight, $9 target By Investing.com - Investing.com UK

May 28, 2026

May 27, 2026

CLLSCellectis ADR Stock Price and Quote - Finviz

May 27, 2026

May 22, 2026

Cellectis’s SWOT analysis: biotech stock shows promise in CAR-T therapy - Investing.com

May 22, 2026

May 19, 2026

CLLS Stock Price, Quote & Chart | CELLECTISADR (NASDAQ:CLLS) - ChartMill

May 19, 2026

May 12, 2026

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress - ChartMill

May 12, 2026

May 11, 2026

Cellectis Reports Financial Results for the First Quarter 2026 - ChartMill

May 11, 2026

Apr 27, 2026

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting - ChartMill

Apr 27, 2026

Apr 21, 2026

European ADRs Open Lower As Telecoms And Biotech Split - Finimize

Apr 21, 2026

Apr 14, 2026

Cellectis stock rating held at outperform on allogeneic platform - Investing.com

Apr 14, 2026

Apr 13, 2026

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform - ChartMill

Apr 13, 2026

Apr 10, 2026

European ADRs Headed For A Strong Week In US Trading - Finimize

Apr 10, 2026

Apr 07, 2026

Monthly information on share capital and company voting rights - ChartMill

Apr 07, 2026

Mar 23, 2026

Citizens reiterates Cellectis stock rating on CAR-T progress - Investing.com

Mar 23, 2026

Mar 20, 2026

Cellectis earnings beat by $0.10, revenue topped estimates - Investing.com

Mar 20, 2026

Mar 20, 2026

Earnings call transcript: Cellectis beats Q4 2025 forecasts, stock rises - Investing.com

Mar 20, 2026

Mar 19, 2026

Cellectis (NASDAQ: CLLS) 2025 annual report shows losses and funding runway - Stock Titan

Mar 19, 2026

Mar 19, 2026

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - ChartMill

Mar 19, 2026

Mar 12, 2026

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - ChartMill

Mar 12, 2026

Feb 26, 2026

European ADRs Slipped As Biopharma Dragged The Pack - Finimize

Feb 26, 2026

Feb 26, 2026

European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize

Feb 26, 2026

Feb 24, 2026

European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize

Feb 24, 2026

Feb 17, 2026

Jefferies assumes coverage on Cellectis stock with Buy rating - Investing.com

Feb 17, 2026

Jan 26, 2026

European ADRs Started The Week Higher In US Trading - Finimize

Jan 26, 2026

Dec 29, 2025

Traders are paying attention to the gapping stocks in Monday's session. - ChartMill

Dec 29, 2025